Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

A federal judge has rejected Bayer AG's proposed $648 million settlement of class-action litigation by cities and other claimants over contamination from polychlorinated biphenyls, or PCBs, made by the former Monsanto Co.

U.S. judge rejects $648 million Bayer PCB contamination settlement

Biogen

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Intel

Lockheed Martin

Altria

Merck

Philip Morris

Roche Holding AG

Sanofi

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The December 2020 Heat Map

Bayer waded deeper into digital health with its  G4A Digital Health Partnerships accelerator program , in which it'll collaborate with five new startups from around the world on digital health solutions, including digital therapeutics (DTx) for chronic conditions, personalized medicine, and AI-driven disease management.

Bayer doubles down on digital health—making it an early mover in the slow-to-digitize pharma space

ST. LOUIS--(BUSINESS WIRE)--Bayer Fund, a philanthropic arm of life sciences company Bayer, today awarded $3.9 million in grants to 80 charities and non-profit organizations throughout the United States, $300,000 of which is dedicated to supporting initiatives related to COVID-19. Each grant will go toward a program that contributes to one or more of Bayer Fund's key focus areas: health and wellness, food and nutrition, community development and STEM Education. The St. Louis Area Foodbank, Urba

Bayer Fund Awards $3.9 Million in Grants throughout the United States

All growers are not created equal. At least, that was the mindset that Bayer and other agriculture giants had — until now.   While many farmers are capable of growing standard soybean crops, companies like Bayer often release specific seeds that can produce higher yields or healthier end-products. Those crops require more oversight on the part of a provider like Bayer — including site visits to watch the seeds get planted, for example — to ensure farmers are complying with the more stringent growing protocols. That's why Bayer and others have to limit access to those speciality product.

Why it was a 'no brainer' for ag giant Bayer to launch the industry's first blockchain initiative to track crops from seed-to-sale with startup partner BlockApps

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug finerenone, compared to placebo, reduced the risk of cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), with or without history of cardiovascular disease (CVD).1,2 The findings were presented in a Late-Breaking session today at the American Heart Associ

Bayer Presents FIDELIO-DKD Phase III Study Cardiovascular Subgroup Analysis of Patients With Chronic Kidney Disease and Type 2 Diabetes

With immobile stock prices and a hangover of legal issues, these CEOs might be glad Wall Street doesn't operate like a democracy.

Investors Wish They Could Vote These 2 Healthcare CEOs Out

EMERYVILLE, Calif., US, and LEVERKUSEN, Germany--(BUSINESS WIRE)--Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a USD 65 million Series A financing round and emerged from stealth mode today. The Series A round was led by Leaps by Bayer and Humboldt Fund. Other investors included Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital. CRISPR-based gene editing is one of the most important discoveries in recent years,

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Alexion Pharma

Amgen

Regeneron Pharmaceuticals

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared first on Investor's Business Daily.

These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable

A court-appointed mediator on Monday said Bayer AG has made "substantial progress" toward resolving tens of thousands of remaining claims that its Roundup weedkiller causes cancer.

Bayer makes 'substantial progress' in Roundup cancer lawsuits, mediator says

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of the investigational drug finerenone, for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Finerenone is a potential first-in-class investigational non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that d

Bayer Submits Regulatory Applications for Investigational Drug Finerenone in the U.S. and the EU for Patients with Chronic Kidney Disease and Type 2 Diabetes

Bayer's CEO and two fellow executive board members purchased a collective 2.9 million euros ($3.5 million) worth of the German drugmaker's shares after the stock was battered by billions in writedowns, litigation woes and a bleaker profit outlook.

Bayer executives buy 2.9 million euro in battered stock after writedowns

Bayer AG (ETR: BAYN) said on Tuesday that it concluded the fiscal third quarter with a net loss. The company also reiterated its guidance for 2020.

Bayer AG swings to a net loss of £2.46 billion in the fiscal third quarter

Werner Enterprises

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q3 2020 Results - Earnings Call Transcript

Bayer Aktiengesellschaft's (BAYZF) CEO Werner Baumann On Q3 2020 Results - Quick Version Earnings Call Transcript

Bayer (BAYRY) misses both earnings and sales estimates in the third quarter of 2020.

Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y

Drugs and farming pesticides maker Bayer said the costs of its settlement over claims its Roundup weedkiller causes cancer, initially put at $11 billion, would be $750 million higher.

Bayer flags $750 million higher Roundup settlement bill

CVS Health

Fresenius Medical Care

Despite the correction, stocks - especially US stocks - are still trading at very high multiples and it is difficult to find bargains. Bayer and Fresenius are two German large-cap stocks that are trading at depressed levels.

Picks For October: 2 German And 2 U.S. Stocks

Bayer has made a big bet on gene therapy by announcing the acquisition of U.S. biotech firm Asklepios BioPharmaceutical for as much as $4 billion.

ETFs in Focus on Bayer's Bet on Gene Therapy

The U.S. Environmental Protection Agency will allow farmers for the next five years to spray crops with a Bayer AG weed killer that a U.S. appeals court blocked sales of in June, Administrator Andrew Wheeler said on RFD TV on Tuesday.

U.S. EPA approves use of Bayer weed killer for five years: RFD TV

PITTSBURGH--(BUSINESS WIRE)--Bayer announced its plans to build a new 220,000 sq. ft. Distribution Center to support the ongoing growth of Bayer's Radiology global business that supplies medical device products world-wide. A 10-year lease with optional extensions is being negotiated. The facility, which will be operated and staffed by FedEx Supply Chain, is in response to growing product demand and steady growth of the business over the past few years. It allows for flexibility for future growt

Bayer Signs Letter of Intent to Build New Distribution Center in Saxonburg, PA

Bayer (BAYRY) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 3.

Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards?

Bayer, following the Monsanto M&A, has become one of the largest agrochemical company in the world. I wouldn't touch the company at normal valuation currently, following the liability risks.

Bayer: Consider The Company At Dirt-Cheap Valuation

The $4 billion deal will give the company's presence in the gene therapy space a huge boost.

Bayer to Acquire a Lead Position in America's Gene Therapy Space

German pharma and life sciences company Bayer AG (OTC: BAYRY) has acquired U.S.-based gene therapy biotech company Asklepios Biopharmaceutical Inc (AskBio) in a deal valued up to $4 billion. The purchase price of $2 billion will be paid upfront, and the remaining half will be payable in success-based milestone payments.

News for Bayer AG Stock (BAYRY)